The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.

doi:10.1007/BF02171051

Back to search

Article

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.

Biotherapy (Dordrecht, Netherlands) - 1 Jan 1992

Bos R, Nieuwenhuizen W

Abstract excerpt

The generation of the proteolytic enzyme plasmin from its inactive precursor plasminogen, mediated by so called plasminogen activators, is the essential step in thrombolytic therapy. Plasmin is responsible for the degradation of the insoluble fibrin, the major component of a thrombus, to soluble...

Topics

Animals
Antibodies, Monoclonal
Fibrinolytic Agents
Humans
Mutation
Thrombolytic Therapy
Tissue Plasminogen Activator
Urokinase-Type Plasminogen Activator

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.